Stephen Liu
MD
Chief of Hematology and Oncology
Georgetown University
Nov 02, 2026
Episode
395
Soundcloud
Share
In this episode of Lung Cancer Considered, Drs. Jacob Sands, Ferdinandos Skoulidis, and Jarushka Naidoo discuss key research highlights from ESMO 2026, including results from the DeLLphi-305 trial evaluating tarlatamab in extensive-stage small cell lung cancer and the KRAScendo-1 trial investigating divarasib in KRAS G12C-mutated NSCLC. The discussion also explores emerging immunotherapy strategies, including findings from the MOIO and OptiTROP-Lung06 studies, advances in predicting immune-related toxicities, and the potential implications of these developments for clinical practice.
Guest
Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Jaruska Naidoo
MD
Professor of Medical Oncology
Consultant, Medical Oncologist at Beaumont Hospital
Royal College of Surgeons
Jacob Sands
MD
Assistant Professor of Medicine, Harvard Medical School
Associate Chief, Lowe Center for Thoracic Oncology
Dana Farber Cancer Institute
Ferdinandos Skoulidis
MD, PhD
Professor, Department of Thoracic and Head and Neck Medical Oncology
University of Texas MD Anderson Cancer Center
